Prognostic value of HMGB 1 in early breast cancer patients under neoadjuvant chemotherapy
نویسندگان
چکیده
منابع مشابه
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high-mobility group box 1 protein (HMGB1) in the circulation. Here, we investigate whether this increa...
متن کاملAssociation of tumor infiltration lymphocytes and complete pathological response in breast cancer patients under neoadjuvant chemotherapy
Background: The breast cancer is the most common type of cancer in Iran. Hence determination of the optimal treatment and the contributing factors are important. The main aim in current study was to determine the association between tumor infiltration of lymphocytes (TIL) and complete pathological response in breast cancer patients after neoadjuvant chemotherapy. Methods and materials: In this...
متن کاملPrognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study
The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NCT). This prospective observational study aimed to evaluate the prognostic impact of receptor conversion in breast cancer patients treated with NCT.Of the 423 consecutive patients who had residual disease in the breast after ...
متن کاملPrognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
Background and objective:Breast cancer is the most common malignancy among women. The Neoadjuvant chemotherapy is the treatment of choice for non-operable tumors. The Ki67 is a proliferation marker that can be used to predict the therapeutic response to chemotherapy and the patients' prognosis. Methods: This retrospective study was carri...
متن کاملThe Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
BACKGROUND A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Medicine
سال: 2016
ISSN: 2045-7634,2045-7634
DOI: 10.1002/cam4.827